Continuing Education Activity

Myotonia congenita is a hereditary skeletal muscle channelopathy arising from mutations in the CLCN1 gene encoding the chloride channel. Impaired chloride conductance leads to abnormal sarcolemmal excitability and delayed muscle relaxation following contraction. Clinical manifestations include muscle stiffness, transient weakness, and exercise-induced symptoms that may fluctuate with activity, temperature, or emotional stress. Two phenotypic variants are recognized: the autosomal dominant Thomsen disease and the autosomal recessive Becker disease, which often presents with more severe weakness.

Diagnosis is established through clinical evaluation, electromyography demonstrating myotonic discharges, and genetic testing to confirm CLCN1 mutations. Management focuses on symptom control with sodium channel blockers such as mexiletine, alongside physiotherapy, patient education, and genetic counseling. Potential complications include anesthesia-related risks and functional limitations from recurrent stiffness. Prognosis is generally favorable, with most patients maintaining normal life expectancy, although disease burden varies with phenotype and response to therapy.

This activity for healthcare professionals is designed to strengthen learners’ competence in evaluating and managing myotonia congenita. Participants will deepen their understanding of genotype-phenotype variation, diagnostic challenges, and evidence-based treatment approaches, including sodium channel blockade. Application of these skills advances interprofessional care, ensures effective counseling, and improves long-term quality of life.

Objectives:

• Identify the phenotypic and diagnostic characteristics of myotonia congenita, emphasizing the differences between Becker and Thomsen disease.
• Apply evidence-based, personalized strategies for managing myotonia congenita and mitigating its possible complications.
• Implement effective counseling and education based on genetic findings to promote adherence and optimize long-term outcomes in myotonia congenita.
• Collaborate with the interprofessional team to educate, treat, and monitor patients with myotonia congenita to improve health outcomes, optimize quality of life, and support informed family planning.

Access free multiple choice questions on this topic.

Introduction

Myotonia congenita is a genetic muscular channelopathy that affects skeletal muscle fibers under somatic control.[1] Myotonia, defined as delayed relaxation after skeletal muscle contraction, is the hallmark of the disorder and produces prolonged rigidity with stiffness, cramping, and muscle hypertrophy. The condition results from mutations in the CLCN1 chloride channel gene, which encodes the voltage-gated chloride channel protein 1 (ClC-1) in the sarcolemmal membrane.[2] ClC-1 is the predominant chloride channel in the sarcolemma, accounting for approximately 80% of resting muscle membrane conductance.[3] Dysfunction of this channel causes sarcolemmal hyperexcitability, leading to repetitive depolarization and clinical myotonia.[4]

Historically, myotonia congenita has been classified into 2 forms: Becker and Thomsen disease. Becker disease is inherited in an autosomal recessive pattern and typically associated with more severe myotonia that can progress to permanent weakness. Thomsen disease follows an autosomal dominant pattern, presents earlier in childhood, and usually produces milder features.[5] Advances in sequencing have identified more than 200 pathogenic CLCN1 mutations.[6] Increasing knowledge of genotype-phenotype correlations has blurred the distinction between Becker and Thomsen disease, revealing broader clinical variability.

Etiology

In skeletal muscle, action potentials are generated through the activation of voltage-gated sodium channels, resulting in depolarization of the sarcolemmal membrane. Unlike neurons, chloride channels are the principal drivers of repolarization. ClC-1 is the predominant chloride channel in the sarcolemmal membrane, contributing to 80% of resting muscle membrane conductance.

Myotonia congenita stems from defective ClC-1 channels due to mutations in the CLCN1 gene.[7][8] The resulting defect confers hyperexcitability through impaired repolarization of the muscle membrane. The faulty ClC-1 channels reduce chloride conductance across the sarcolemma, impairing the ability of skeletal muscle to maintain physiological excitability. Since ClC-1 accounts for most of the resting muscle membrane conductance, CLCN1 mutations significantly increase skeletal muscle input resistance.[9]

ClC-1 channels also counteract the depolarizing effect of excessive extracellular potassium accumulation during repeated action potentials. In healthy individuals, this elevated potassium concentration is balanced by functional ClC-1 channels. Loss of this stabilizing effect, as in myotonia congenita, renders the membrane highly sensitive to even minor potassium fluctuations. These small variations can trigger spontaneous action potentials, further potentiating myotonic symptoms. This mechanism explains why sodium channel blockade is a major therapeutic strategy in myotonia congenita.

Epidemiology

The frequency of myotonia congenita was historically estimated at 1 in 23,000 for the autosomal dominant form and 1 in 50,000 for the autosomal recessive type. More recent data indicate that the dominant form is less common than the recessive type. In a U.K. cohort of 300 patients, only 37% carried autosomal dominant mutations.[10] Both forms occur with higher prevalence in Northern Scandinavia, reaching 1 in 10,000, which is approximately 10 times greater than the worldwide prevalence.[11][12][13]

History and Physical

The cardinal feature of myotonia congenita is delayed relaxation of contracted skeletal muscle.[14] Considerable phenotypic variability occurs in both autosomal dominant and autosomal recessive forms, which can hinder timely diagnosis and management. Identical CLCN1 mutations may produce markedly different clinical presentations, reflecting the complexity of genotype-phenotype correlations in these channelopathies.[15] Conversely, some mutations give rise to highly consistent phenotypes. Detailed family history may help clarify the inheritance pattern, although this information may be absent in sporadic cases.

In early childhood, symptoms may include feeding difficulties such as dysphagia, reflux, gagging, and choking. Children may appear clumsy and fall frequently even after walking is established. Difficulty opening the eyes after prolonged contraction, such as crying, may also be observed. These signs may be subtle, making careful history from patients and caregivers, as well as clinical examination, essential. Symptoms often progress after onset and then plateau.[16]

Muscle stiffness in myotonia congenita often improves with exercise or repetitive movement, a phenomenon termed the “warm-up effect,” which is rapidly lost after cessation of activity. Men appear to be more severely affected than women. Symptoms also often worsen during pregnancy and menstruation, suggesting that sex hormones influence ClC-1 channel function.[17][18]

Myotonia congenita is classically divided into distinct clinical entities based on the mode of inheritance, with Becker and Thomsen disease being the 2 primary forms. Despite subtle differences between these conditions, the phenotypic variability discussed above means that the ultimate diagnosis is confirmed with genetic testing.

Becker disease is inherited in an autosomal recessive manner and associated with moderate-to-severe myotonia and transient weakness, which may become progressive in some cases.[19] The disease generally presents later in childhood than Thomsen disease.[20] Muscle hypertrophy is more prominent in Becker disease, particularly in the larger muscle groups of the lower limbs.

Thomsen disease is inherited in an autosomal dominant pattern and typically associated with an earlier onset of symptoms, although the manifestations are milder than in Becker disease. The mild, progressive, permanent weakness often described in Becker disease does not occur in Thomsen disease.[21] Autosomal dominant mutations responsible for Thomsen disease demonstrate reduced penetrance, and identical mutations inherited across generations can result in markedly different phenotypes.

Evaluation

Clinical examination often reveals myotonia, which may be elicited by asking patients to open and close their eyes or fists repeatedly. Repeated tapping of a muscle can similarly induce myotonia, and patients may have difficulty extending the fingers immediately after a handshake. The warm-up effect, where stiffness improves with repeated activity, may also be demonstrable.

Biochemical investigations are usually unremarkable, although mild elevations of creatine kinase up to 3 to 4 times the upper limit of normal have been described. Electromyography (EMG) is useful in evaluating patients with myotonia, but the technique is time-consuming, uncomfortable, and may yield overlapping findings across different skeletal muscle channelopathies.[22] Diffuse myotonic discharges with spontaneous bursts of electrical activity are typically demonstrated. EMG does not distinguish between autosomal dominant and autosomal recessive myotonia congenita. Given the widespread availability of molecular diagnostics, muscle biopsy is now rarely performed. When obtained, biopsies may show heterogeneous fiber size, increased central nuclei, and absence of type 2B fibers, but these findings are not required to establish the diagnosis.[23]

Genetic testing is considered the gold standard for diagnosis. The most commonly implicated gene is CLCN1, which encodes the skeletal muscle chloride channel ClC-1. However, no pathogenic CLCN1 variants are identified in many patients with a convincing clinical phenotype.

A multigene panel is generally recommended as the initial approach. Such panels include CLCN1 and other genes of interest, notably SCN4A, which encodes the skeletal muscle sodium channel Nav1.4 and is relevant in the differential diagnosis. Testing should be performed in specialized centers where appropriate methodologies are used to evaluate variants of uncertain significance, correlate identified mutations with clinical features, and limit costs. Broader genomic methods, such as exome sequencing or mitochondrial sequencing, may be pursued if no causative variant is identified on panel testing.[24][25]

Treatment / Management

Pharmacological management of myotonia congenita is not always indicated, and a neurologist should evaluate patients to determine the need for medication before initiation.[26] Lifestyle modifications include avoidance of identified triggers such as stress and cold. Exercise, particularly gymnastics, has been anecdotally reported to relieve myotonia, although this observation requires further investigation.

Medications are generally intended to reduce muscle membrane hypersensitivity by blocking sodium ion flow.[27][28] Mexiletine is the most commonly prescribed drug, but use requires electrocardiographic monitoring of the QT interval before and during treatment.[29] This agent is classified as a class Ib antiarrhythmic and is structurally related to the local anesthetic lidocaine. Mexiletine is primarily used to manage ventricular arrhythmias by blocking the rapid sodium influx responsible for phase 0 of the action potential, thereby shortening the action potential and prolonging the refractory period.[30] Reported adverse effects include tremor, dizziness, ataxia, and gastrointestinal disturbance. These effects are usually dose-dependent and reversible after dose reduction or discontinuation.

Other sodium channel anticonvulsants such as phenytoin, carbamazepine, oxcarbazepine, and lamotrigine are also commonly used.[31] Acetazolamide is effective as well, particularly in children, because of its favorable safety profile.[32]

Potassium channels have emerged as a novel therapeutic target. The potassium channel activator retigabine has been investigated in murine models of myotonia congenita, where it significantly reduced myotonia severity in vivo. However, evidence to guide pharmacological management is limited.[33]

Special caution is required when treating individuals with myotonia congenita during anesthesia, particularly with depolarizing agents. Muscle spasms and ventilation difficulties have been reported with the use of suxamethonium in patients with this condition.[34]

Differential Diagnosis

Myotonia congenita is the most common nondystrophic myotonia. The condition is termed "nondystrophic" because muscle tissue is not structurally compromised in the disease process. Instead, defective ion channels in skeletal muscle alter ion conductance and produce myotonia. Dysfunction of chloride channels characterizes myotonia congenita, whereas mutations in sodium channel genes cause other nondystrophic myotonias, including paramyotonia congenita, potassium-aggravated myotonia, and hyperkalemic periodic paralysis. Mutations in the SCN4A gene lead to abnormal function of voltage-gated sodium channels.

Symptoms of myotonia congenita are often most pronounced in the lower limbs, with patients frequently experiencing difficulty rising quickly from a seated position. In contrast, paramyotonia congenita more severely affects the eyes and face. Myotonia associated with hyperkalemic periodic paralysis is generally mild and commonly involves the eyelids and tongue. 

Potassium channel disorders typically worsen after ingestion of potassium-rich foods, and patients often describe their myotonia as painful, a feature not characteristic of myotonia congenita. Careful evaluation of precipitating and relieving factors, associated systemic disease, and EMG findings often permits clinical distinction between myotonia congenita and other channelopathies.

Myotonic dystrophies are another important differential diagnosis in infants and children with muscle weakness and spasticity. Myotonic dystrophy types 1 and 2 are associated with systemic features such as endocrine dysfunction, cardiac conduction defects, and cataract formation. The distribution of muscle weakness in myotonic dystrophy is also distinct from that observed in myotonia congenita.

Prognosis

Neither autosomal nor recessively inherited myotonia congenita is associated with systemic effects or reduced life expectancy. Prognosis differs markedly from that of myotonic dystrophy, which makes accurate diagnosis essential. Symptoms of myotonia congenita generally do not progress once they appear. Becker disease is typically associated with more severe manifestations than Thomsen disease, and permanent weakness may persist. Genetic counseling is important to support informed decisions about family planning.

Complications

Care must be taken during anesthesia, particularly with depolarizing muscle relaxants, which have been associated with adverse events in patients with myotonia congenita, including profound muscle spasm and difficulty with ventilation. Medications that should be avoided, or used only with caution, include the following:

• Suxamethonium: may produce severe muscle spasm and ventilation difficulties
• Adrenaline and β-agonists: may aggravate symptoms
• β-antagonists: may increase symptom severity
• Colchicine: may trigger myopathy, particularly in patients with renal insufficiency

Pregnancy has been associated with worsening of myotonia congenita, which necessitates interprofessional management throughout gestation, delivery, and the postpartum period.

Deterrence and Patient Education

Education and support for patients with myotonia congenita and their families are essential. The physical manifestations of myotonia can be severely debilitating and impose a significant psychological burden. Muscle hypertrophy may contribute to stigmatization, as patients are sometimes perceived as able-bodied and subsequently discriminated against. Attempts to forcibly overcome myotonia can worsen symptoms, and stress is a well-recognized exacerbating factor. Thus, coping strategies that prioritize psychological well-being and optimize function are critical. Environmental adjustments at home, school, and work may reduce the risk of falls and mitigate injury when such traumatic events occur. Dietary modifications may also be necessary to promote safe swallowing and lower the risk of aspiration.

Enhancing Healthcare Team Outcomes

Myotonia congenita is a rare inherited muscular channelopathy characterized by delayed relaxation of skeletal muscles. The condition results from mutations in the CLCN1 gene, which encodes the ClC-1 chloride channel. Two clinical phenotypes of the disorder have been described. Thomsen disease follows an autosomal dominant inheritance pattern, while Becker disease is inherited in an autosomal recessive manner. Both forms share overlapping features. The diagnosis is made with a combination of clinical, electrophysiological, and genetic studies. Pharmacologic management of myotonia congenita relies predominantly on sodium channel blockers.

Myotonia congenita is a highly variable but potentially devastating condition affecting patients and their families from early childhood throughout their lives. With the genetic nature of the condition, testing and counseling support the evaluation of family members and family planning. Therefore, effective and safe care of patients with myotonia congenita requires coordination among several medical specialties, including pediatrics and clinical genetics, as well as input from physiotherapists, dieticians, occupational therapists, and psychologists. The role of this interprofessional team is now well-established in specialized centers.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Lossin C, George AL. Myotonia congenita. Adv Genet. 2008;63:25-55. [PubMed: 19185184]

2.

Conravey A, Santana-Gould L. Myotonia congenita and myotonic dystrophy: surveillance and management. Curr Treat Options Neurol. 2010 Jan;12(1):16-28. [PubMed: 20842486]

3.

Kubota T, Takahashi MP. Molecular genetics of skeletal muscle channelopathies. J Hum Genet. 2025 Aug 06; [PubMed: 40770230]

4.

Platt D, Griggs R. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol. 2009 Oct;22(5):524-31. [PMC free article: PMC2763141] [PubMed: 19571750]

5.

Sun C, Tranebjaerg L, Torbergsen T, Holmgren G, Van Ghelue M. Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia. Eur J Hum Genet. 2001 Dec;9(12):903-9. [PubMed: 11840191]

6.

Li L, McCall C, Hu X. Editorial: Innate Immunity Programming and Memory in Resolving and Non-Resolving Inflammation. Front Immunol. 2020;11:177. [PMC free article: PMC7026667] [PubMed: 32117304]

7.

Zhang J, Bendahhou S, Sanguinetti MC, Ptácek LJ. Functional consequences of chloride channel gene (CLCN1) mutations causing myotonia congenita. Neurology. 2000 Feb 22;54(4):937-42. [PubMed: 10690989]

8.

Tang CY, Chen TY. Physiology and pathophysiology of CLC-1: mechanisms of a chloride channel disease, myotonia. J Biomed Biotechnol. 2011;2011:685328. [PMC free article: PMC3237021] [PubMed: 22187529]

9.

Lipicky RJ, Bryant SH, Salmon JH. Cable parameters, sodium, potassium, chloride, and water content, and potassium efflux in isolated external intercostal muscle of normal volunteers and patients with myotonia congenita. J Clin Invest. 1971 Oct;50(10):2091-103. [PMC free article: PMC292143] [PubMed: 4940295]

10.

Fialho D, Schorge S, Pucovska U, Davies NP, Labrum R, Haworth A, Stanley E, Sud R, Wakeling W, Davis MB, Kullmann DM, Hanna MG. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain. 2007 Dec;130(Pt 12):3265-74. [PubMed: 17932099]

11.

Coote DJ, Davis MR, Cabrera M, Needham M, Laing NG, Nowak KJ. Clinical Utility Gene Card for: autosomal dominant myotonia congenita (Thomsen Disease). Eur J Hum Genet. 2018 Jul;26(7):1072-1077. [PMC free article: PMC6018704] [PubMed: 29695755]

12.

Papponen H, Toppinen T, Baumann P, Myllylä V, Leisti J, Kuivaniemi H, Tromp G, Myllylä R. Founder mutations and the high prevalence of myotonia congenita in northern Finland. Neurology. 1999 Jul 22;53(2):297-302. [PubMed: 10430417]

13.

Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991;1(1):19-29. [PubMed: 1822774]

14.

Vivekanandam V, Munot P, Jayaseelan DL. Pediatric neuromuscular channelopathies. Handb Clin Neurol. 2024;203:111-122. [PubMed: 39174243]

15.

Morales F, Pusch M. An Up-to-Date Overview of the Complexity of Genotype-Phenotype Relationships in Myotonic Channelopathies. Front Neurol. 2019;10:1404. [PMC free article: PMC6978732] [PubMed: 32010054]

16.

Kuhn E. [Myotonia congenital (Thomsen) and recessive generalized myotonia (Becker)]. Nervenarzt. 1993 Dec;64(12):766-9. [PubMed: 8114977]

17.

Colding-Jørgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve. 2005 Jul;32(1):19-34. [PubMed: 15786415]

18.

Fialho D, Kullmann DM, Hanna MG, Schorge S. Non-genomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita. Neuromuscul Disord. 2008 Nov;18(11):869-72. [PubMed: 18815035]

19.

Krovvidi S, Nelakurthi S, Gedela M, Singamsetty S, Bhimireddy V. Autosomal Recessive Becker's Form of Myotonia Congenita in Indian Families. Cureus. 2025 May;17(5):e84373. [PMC free article: PMC12176253] [PubMed: 40535402]

20.

Dunø M, Colding-Jørgensen E, Grunnet M, Jespersen T, Vissing J, Schwartz M. Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype. Eur J Hum Genet. 2004 Sep;12(9):738-43. [PubMed: 15162127]

21.

Richardson RC, Tarleton JC, Bird TD, Gospe SM. Truncating CLCN1 mutations in myotonia congenita: variable patterns of inheritance. Muscle Nerve. 2014 Apr;49(4):593-600. [PubMed: 23893571]

22.

Phillips L, Trivedi JR. Skeletal Muscle Channelopathies. Neurotherapeutics. 2018 Oct;15(4):954-965. [PMC free article: PMC6277285] [PubMed: 30341599]

23.

Hahn C, Salajegheh MK. Myotonic disorders: A review article. Iran J Neurol. 2016 Jan 05;15(1):46-53. [PMC free article: PMC4852070] [PubMed: 27141276]

24.

Okur Altındaş B, Zamani AG, Güney F, Yildirim MS. Uncovering the CLCN1 Y150* nonsense variant in myotonia congenita: genetic evidence from segregation analysis. Acta Neurol Belg. 2025 Oct;125(5):1461-1464. [PubMed: 40782174]

25.

Wang X, Wang S, Qi H, Wu B, He M, Zhang G. Clinical and genetic analysis and literature review of children with myotonia congenita due to CLCN1 mutations. Ital J Pediatr. 2025 Jun 09;51(1):183. [PMC free article: PMC12150482] [PubMed: 40490814]

26.

Gutmann L, Phillips LH. Myotonia congenita. Semin Neurol. 1991 Sep;11(3):244-8. [PubMed: 1947487]

27.

Dupont C, Denman KS, Hawash AA, Voss AA, Rich MM. Treatment of myotonia congenita with retigabine in mice. Exp Neurol. 2019 May;315:52-59. [PMC free article: PMC6431423] [PubMed: 30738808]

28.

Spillane J, Trip J, Drost G, Faber CG, Hanna MG, Nevitt SJ, Vivekanandam V. Drug treatment for myotonia. Cochrane Database Syst Rev. 2025 Apr 08;4(4):CD004762. [PMC free article: PMC11977047] [PubMed: 40197813]

29.

Roberts K, Kentris M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 1, 2023. Myotonia. [PubMed: 32644698]

30.

Singh S, Chauhan S, Zeltser R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 26, 2023. Mexiletine. [PubMed: 30085587]

31.

Manolis AS, Deering TF, Cameron J, Estes NA. Mexiletine: pharmacology and therapeutic use. Clin Cardiol. 1990 May;13(5):349-59. [PubMed: 2189614]

32.

Markhorst JM, Stunnenberg BC, Ginjaar IB, Drost G, Erasmus CE, Sie LT. Clinical experience with long-term acetazolamide treatment in children with nondystrophic myotonias: a three-case report. Pediatr Neurol. 2014 Oct;51(4):537-41. [PubMed: 25042881]

33.

Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004762. [PMC free article: PMC9036524] [PubMed: 16437496]

34.

Farbu E, Søfteland E, Bindoff LA. Anaesthetic complications associated with myotonia congenita: case study and comparison with other myotonic disorders. Acta Anaesthesiol Scand. 2003 May;47(5):630-4. [PubMed: 12699527]

Disclosure: Elizabeth Forouzanfar declares no relevant financial relationships with ineligible companies.

Disclosure: Forshing Lui declares no relevant financial relationships with ineligible companies.

Disclosure: Mahdi Alsaleem declares no relevant financial relationships with ineligible companies.